According to a new research report “Systemic Lupus Erythematosus Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Systemic lupus erythematosus currently exhibits a pipeline with 57 drug candidates.
Systemic lupus erythematosus pipeline offers novel therapeutic targets for the treatment of systemic lupus erythematosus
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates, of which four drug candidates are in Phase III stage, 21 drug candidates are in Phase II stage, 20 drug candidates are in Phase I stage, 11 drug candidates are in Pre-Clinical stage and one drug candidates is in the Discovery stage. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.
Insights on pipeline segments
As per the findings of the research, around 25.0% of drug candidates of systemic lupus erythematosus pipeline are being developed to be administered by subcutaneous route, 19.0% by oral route, 17.0% by intravenous route and 14.0% are to be administered by other routes which includes topical, infusion and intramuscular.
Many companies are involved in the development of systemic lupus erythematosus pipeline, with their products in different phases. Anthera Pharmaceuticals, Inc. and AstraZeneca plc have their drug candidates in the Phase III stage of development. Janssen Research & Development, LLC has three drug candidates out of which one is in Phase II stage of development and two are in Phase I stage of development. Merck KGaA also has two drug candidates in Phase II stage of development. Redx Pharma plc has two drug candidates in Pre-Clinical stage of development.
Antibody-drug conjugate (ADC) technology platform for Systemic Lupus Erythematosus drug development
Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.
Phase III – Highest stage of development for Systemic Lupus Erythematosus
There are four systemic lupus erythematosus drug candidates in the Phase III stage of development. Anifrolumab is a Phase III stage drug candidate being developed by AstraZeneca plc for the treatment of systemic lupus erythematosus. It is a monoclonal antibody that inhibits the activity of all type I interferons including IFN-α, IFN-β and IFN-ω. The drug candidate is being developed to be administered by intravenous route.
Major companies collaborate for the development of Systemic Lupus Erythematosus Pipeline
The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline. In October 2015, XTL Biopharmaceuticals Ltd. announced an agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the license agreement signed between the parties in January 2014 for the development of hCDR1, for the treatment of systemic lupus erythematosus. In September 2010, Bristol-Myers Squibb Company and ZymoGenetics, Inc. signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash.
Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA, Eli Lilly and Company, Janssen Research & Development, LLC, Redx Pharma plc and AstraZeneca plc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Company Name: P&S Market Research
Contact Person: Abhishek
Address:347 5th Ave. #1402- 210
City: New York City
State: New York
Country: United States